Discovery of novel aldose reductase inhibitors using a protein structure-based approach: 3D-database search followed by design and synthesis

Journal of Medicinal Chemistry

Volumn 44, Issue 11, 2001, Pages 1718-1728

  Iwata, Y ^a   Arisawa, M ^b   Hamada, R ^b   Kita, Y ^b   Mizutani, M Y ^c   Tomioka, N ^c   Itai, A ^c   Miyamoto, S ^a  

^a DAIICHI SANKYO CO   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c Inst of Medicinal Molecular Design   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR;

ARTICLE; BINDING SITE; BIOASSAY; CONCENTRATION RESPONSE; CRYSTAL STRUCTURE; DATA BASE; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; HYDROPHOBICITY; IC 50; LIGAND BINDING; NONHUMAN; PROTEIN STRUCTURE; STRUCTURE ANALYSIS;

ALDEHYDE REDUCTASE; BINDING SITES; COMBINATORIAL CHEMISTRY TECHNIQUES; CRYSTALLOGRAPHY, X-RAY; DATABASES, FACTUAL; DRUG DESIGN; ENZYME INHIBITORS; INDOLES; LIGANDS; MODELS, MOLECULAR; STEREOISOMERISM;

EID: 0035942512     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000483h     Document Type: Article

References (45)

1. The role of aldose reductase in the development of diabetic complications
2. Aldose reductase inhibitors and their potential for the treatment of diabetic complications
3. Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches
4. A superfamily of NADPH-dependent reductases in eukaryotes
5. Novel, potent aldose reductase inhibitors: 3,4-Dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazoyl]methyl] -1-phthalazineacetic acid (zopolrestat) and congeners
6. Synthesis of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose inhibitors. Identification of potent, orally active 2-fluoro derivatives
7. Biological activities and quantitative structure-activity relationships of spiro[imidazolidine-4,4′(1′H)-quinazoline]-2,2′,5- (3′H)-triones as aldose reductase inhibitors
8. Development of eparlestat (kinedak), aldose reductase inhibitor
9. An unlikely sugar substrate site in the 1.65 Å structure of the human aldose reductase holoenzyme implicated in diabetic complications
10. An anion binding site in human aldose reductase: Mechanistic implications for the binding of citrate, cacodylate, and glucose 6-phosphate
11. Tyrosin-48 is the proton donor and histidine-110 directs substrate stereochemical selectivity in the reduction reaction of human aldose reductase: Enzyme kinetics and crystal structure of the Y48H mutant enzyme
12. Computer simulation studies of the catalytic mechanism of human aldose reductase
13. Catalytic mechanism of aldose reductase studied by the combined potentials of quantum mechanics and molecular mechanics
14. Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors
15. Computer-aided design of enzyme inhibitors: Recent studies
16. Rational design of potent, bioavailable, nonpeptide cyclic Ureas as HIV protease inhibitors
17. HIV-1 integrase pharmacophore: Discovery of inhibitors through three-dimensional database searching
18. Structure-based drug design: Progress, results and challenges
19. Structure-based strategies for drug design and discovery
20. Structure-based discovery of small molecule inhibitors targeted to protein tyrosine phosphatase 1B
21. Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads
22. Rational automatic search method for stable docking models of protein and ligand
23. Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase
24. Structure-based design of an inhibitor modeled at the substrate active of aldose reductase
25. Structural studies of aldose reductase inhibition
26. New inhibitors of aldose reductase: Antioximes of aromatic aldehydes
27. The protein data bank
28. A method for assessing the side chain orientations of histidine, asparagine, and glutamine as well as the protonation forms of histidine in protein structures
29. Isolation of a noncovalent aldose reductase-nucleotide-inhibitor complex
30. The alrestatin double-decker: Binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant
31. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase
32. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations
33. GREEN: A program package for docking studies in rational drug design
34. The discovery of novel, structurally diverse protein kinase C agonists through computer 3D-database pharmacophore search. Molecular Modeling studies
35. Antitrypanosomiasis drug development based on structures of glycolytic enzymes
36. A general and fast scoring function for protein-ligand interactions: A simplified potential approach
37. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil
38. Refined 1.8 Å structure of human aldose reductase complexed with the potent inhibitor zopolrestat
39. Isoxazolo-[3,4-d]-pyridazin-7-(6H)-ones as a potential substrate for new aldose reductase inhibitors
40. Isolation and properties of lens aldose reductase